New findings from the DESTINY-Breast12 study, published in Nature Medicine on September 13, 2024, highlight the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (mBC), including patients with or without brain metastases.
As the largest prospective study investigating T-DXd in this setting, the trial demonstrated substantial and durable intracranial and overall activity in previously treated patients:
12-month progression-free survival (PFS): 61.6% (brain metastases cohort)
12-month central nervous system PFS: 58.9%
Objective response rate (ORR): 62.7% (non-brain metastases cohort)
Safety: Grade 3+ adverse events occurred in 51% (brain metastases) and 49% (non-brain metastases) of patients.
These results reinforce the role of T-DXd in treating HER2+ mBC, providing strong evidence for its use irrespective of brain metastases status.
A special acknowledgment to the researchers, clinicians, and participants who contributed to this important study, advancing treatment options for patients with metastatic breast cancer.
Read more: https://lnkd.in/dTWMtDRP
